China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the India-headquartered firm exclusive commercialization rights to Beizary, a modified version of docetaxel, in the United States.
Deal Terms
Under the agreement, Beihai will handle manufacturing and supply of Beizary. The company will receive an upfront payment and sales milestone payments totaling USD 25 million, along with high double-digit profit sharing.
Drug Profile
Docetaxel, a widely used anti-tumor drug, contains Tween 80, which can cause severe side effects such as allergies and fluid retention. All marketed docetaxel products carry black box warnings regarding Tween 80’s safety issues. Beizary, approved in the US in October 2022, contains no Tween 80, eliminating associated allergic reactions and significantly improving clinical safety. Clinical trials showed Beizary reduces docetaxel-specific blood toxicity and enhances the drug’s risk-benefit ratio.-Fineline Info & Tech
